Señales en vivo de MYGN | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 15:54):
Our systems believe the stock currently is undervalued by 0.10% compare to its pairs and should correct upwards.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally...

Stats
Volumen de hoy	250 502
Volumen promedio	774 616
Capitalización de mercado	2.17B
EPS	$-0.750 ( Q3 \| 2023-11-07 )
Próxima fecha de ganancias	( $-0.0100 ) 2024-08-01
Last Dividend	$1.750 ( 2009-07-01 )
Next Dividend	$0 ( N/A )
P/E	-8.57 (Sector) 42.63 (Industry) 0
ATR14	$0.0200 (0.08%)

ACRS 8.18%

AKU -17.87%

APDN 32.22%

BDSX -0.65%

BIOC 0.00%

BNGO -2.32%

BNR -2.86%

CDNA -1.09%

CEMI 0.22%

CHEK 3.02%

CNTG 2.76%

CSTL -3.08%

DMTK -11.32%

DRIO -0.84%

EXAS 0.50%

FLDM -7.02%

FLGT 2.60%

GENE -6.04%

GH -2.11%

GTH 0.12%

HTGM 0.00%

ICLR 1.20%

IDXX -2.02%

ILMN 1.31%

ISPC -3.88%

LAB -1.69%

LMDX 0.00%

MDXH -2.51%

ME -4.14%

MEDP -0.85%

MYGN -1.92%

MYNZ -16.98%

NDRA -4.50%

NEO 0.47%

NEOG -3.61%

NOTV -4.82%

NTRA -0.56%

OCDX 0.92%

OLK 0.18%

OPGN -0.39%

OPK -1.60%

PMD -2.89%

PRPO 0.89%

PSNL 1.71%

RDNT -0.59%

SERA 3.38%

SHC -2.82%

SQL 0.00%

STIM -4.17%

STRR -4.19%

STRRP -5.05%

SYNH 0.02%

TRIB 2.90%

TTOO 0.56%

TWST -0.77%

VIVO 0.00%

XGN 0.55%

Insider Trading

Date	Person	Action	Amount	type
2024-06-06	Skovronsky Daniel	Buy	15 695	Common Stock
2024-06-06	Dreismann Heinrich	Buy	15 695	Common Stock
2024-06-06	Newcomer Lee Nisley	Buy	15 695	Common Stock
2024-06-06	Kumar Rashmi	Buy	15 695	Common Stock
2024-06-06	Reitan Colleen F	Buy	15 695	Common Stock

INSIDER POWER
35.27
Last 95 transactions
Buy: 1 228 148 \| Sell: 580 773

Correlación (AI algo v.1.1b): Undervalued: 0.10% $24.03 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Volumen Correlación

Largo: 0.19 (neutral)

Corto: 0.62 (weak)

Signal:(60.273) Neutral

Myriad Genetics Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Myriad Genetics Inc Correlación - Moneda/Commodity

0.54
( weak )

0.47
( neutral )

0.00
( neutral )

0.32
( neutral )

0.00
( neutral )

0.03
( neutral )

Myriad Genetics Inc Finanzas

Annual	2022
Ingresos:	$678.40M
Beneficio Bruto:	$476.40M (70.22 %)
EPS:	$-1.390

FY	2022
Ingresos:	$678.40M
Beneficio Bruto:	$476.40M (70.22 %)
EPS:	$-1.390

FY	2021
Ingresos:	$690.60M
Beneficio Bruto:	$493.00M (71.39 %)
EPS:	$-0.350

FY	2020
Ingresos:	$638.60M
Beneficio Bruto:	$452.50M (70.86 %)
EPS:	$-2.69

Financial Reports:

No articles found.

Myriad Genetics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Myriad Genetics Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$1.750	2009-06-15
Last Dividend	$1.750	2009-07-01
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$3.50	--
Avg. Dividend % Per Year	0.00%	--
Score	2.02	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-09-11)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

2.02

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2009	$3.50	10.20%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
01 Jul 2009	$1.750	30 Nov -0001	30 Nov -0001	30 Nov -0001
15 Jun 2009	$1.750	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2024-09-16	Monthly	14	15.03%	9.60
DMLP	Dividend Diamond	2024-04-26	Quarterly	22	10.71%	9.35
OXSQ	Dividend Diamond	2024-09-16	Monthly	21	12.73%	9.02
ARLP	Dividend Royal	2024-05-07	Quarterly	26	9.67%	8.87
PNNT	Dividend Royal	2024-06-14	Monthly	18	9.49%	8.82
MFIC	Dividend Royal	2024-06-11	Quarterly	21	10.89%	8.79
SPOK	Dividend Royal	2024-05-23	Quarterly	20	8.73%	8.72
PSEC	Dividend Royal	2024-06-25	Monthly	21	9.03%	8.65
SBLK	Dividend Royal	2024-06-06	Quarterly	17	13.10%	8.63
GBDC	Dividend Royal	2024-11-29	Bi-Monthly	15	8.53%	8.62

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.374	1.500	-7.47	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.239	1.200	-7.96	-9.55	[0 - 0.3]
returnOnEquityTTM	-0.350	1.500	-5.00	-7.49	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.268	0.800	8.66	6.93	[1 - 3]
quickRatioTTM	0.963	0.800	9.04	7.23	[0.8 - 2.5]
cashRatioTTM	0.363	1.500	9.09	10.00	[0.2 - 2]
debtRatioTTM	0.175	-1.500	7.08	-10.00	[0 - 0.6]
interestCoverageTTM	-93.79	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.782	2.00	-0.261	-0.521	[0 - 30]
freeCashFlowPerShareTTM	-1.692	2.00	-0.846	-1.692	[0 - 20]
debtEquityRatioTTM	0.295	-1.500	8.82	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.689	1.000	1.852	1.852	[0.2 - 0.8]
operatingProfitMarginTTM	-0.370	1.000	-9.41	-9.41	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.317	1.000	-2.87	-2.87	[0.2 - 2]
assetTurnoverTTM	0.639	0.800	9.07	7.26	[0.5 - 2]
Total Score				-0.0149

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-7.29	1.000	-0.837	0	[1 - 100]
returnOnEquityTTM	-0.350	2.50	-3.21	-7.49	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.692	2.00	-0.564	-1.692	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.782	2.00	-0.261	-0.521	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.389	1.500	-5.92	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0870	1.000	-4.68	0	[0.1 - 0.5]
Total Score				-2.41

Myriad Genetics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.